Inhibrx Biosciences, Inc. ((INBX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inhibrx Biosciences, Inc. is conducting a pivotal clinical study titled ‘An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors.’ The study aims to assess the safety and determine the maximum tolerated dose of INBRX-106, both as a standalone treatment and in combination with pembrolizumab, for patients with various advanced solid tumors. This research is significant as it explores new therapeutic options for conditions like non-small cell lung cancer, melanoma, and renal cell carcinoma.
The study is testing INBRX-106, a hexavalent OX40 agonist antibody, designed to enhance the immune response against tumors. It is administered alone or with pembrolizumab, a well-known anti-PD-1 checkpoint inhibitor, to potentially improve treatment efficacy in solid tumors.
This interventional study is non-randomized and open-label, meaning all participants receive the treatment, and both researchers and participants know what treatment is being administered. The primary purpose is treatment-focused, aiming to establish the safety and optimal dosing of the drug combinations.
The study began on December 11, 2019, with its primary completion and estimated full completion dates yet to be announced. The latest update was submitted on September 10, 2025, indicating ongoing recruitment and data collection efforts.
The potential success of this study could positively influence Inhibrx’s stock performance by demonstrating the viability of INBRX-106 as a novel cancer treatment. This could also impact investor sentiment positively, especially if the study results show promising efficacy and safety. In the competitive landscape of oncology therapeutics, advancements in such trials could position Inhibrx favorably against competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.